Aker BioMarine Group of Oslo, Norway, announces operating revenues in the fourth quarter of 2011 of $17.8 million, up from $15.4 million in the same period for 2010. The operating revenue growth is mainly attributable to higher Superba™ Krill sales. Operating profit before depreciation and amortization (EBITDA) amounted to $1.25 million in the fourth quarter of 2011, compared with a loss of $2.3 million in the fourth quarter of 2010. (All amounts reported are estimates, converted from NOK for the purposes of this release.) Cash flow from operations reflects profit for the reporting period, interest payments, and reduced working capital.
“Aker BioMarine and its customers continue to enjoy significant growth for Superba Krill oil, with a 35% year-over-year growth in Q4,” says Matts Johansen, EVP Sales and Marketing. “We feel that our long term focus on pre-clinical and clinical research to substantiate Superba’s health benefits, sustainable harvesting practices, and being a good partner for our customers are reasons for this success, and this will continue to be our main priority in the future as well.”
Aker BioMarine also recently announced the commission of a second harvesting vessel, the Antarctic Sea. The vessel, which has recently been MSC certified, is currently being improved with new processing equipment and gear. Work is progressing on schedule; Aker BioMarine expects Antarctic Sea to begin harvesting in late March 2012.
“It is important to note that Aker collaborates with conservation- and fishery management groups such as WWF-Norway, CCAMLR, MRAG and others, and actively supports ongoing research on the health of the biomass and impact on other wildlife which consume krill in the area which we harvest,” Johansen commented. “The krill fishery has been stable for many years now, and the small increase we have seen over the last years is all coming from Aker BioMarine. When Aker BioMarine has reached our capacity for both vessels, the total catch will still be significant lower than the trigger level, and the trigger level is just 1/10 of the quota, well within sustainable levels.”
Superba™ Krill is sustainably harvested with eco-friendly methods in the Southern Atlantic Ocean near Antarctica.
Aker BioMarine Antarctic is the only krill ingredient marketer that is primary in its supply. Aker BioMarine Antarctic’s proprietary Eco-Harvesting™ technology and on-board ISO certified processing result in the unique composition of Superba™ Krill Oil and provide full traceability from sea to shelf. The Marine Stewardship Council (MSC) has granted MSC Certification to Aker BioMarine Antarctic’s fisheries validating its sustainable harvesting and traceability, an exclusive distinction. As part of an established commitment to substantiating krill’s health benefits, Aker BioMarine Antarctic continues to sponsor preclinical and clinical trials with krill oil containing omega-3 phospholipids, consistently demonstrating increased tissue accumulation of omega-3 fatty acids and improved blood lipid profiles.
About SuperbaTM KrillOil
Superba™ Krill Oil is a pure, natural source of the health-promoting omega-3 fatty acids eicosapentaenoic acid (EPA) & docosahexaenoic acid (DHA) and the naturally occurring antioxidant astaxanthin. The uniqueness of Superba™ Krill Oil is that the majorityof the omega-3 fatty acids are provided in phospholipid form. In vitro, preclinical and human clinical research has demonstrated the safety and efficacy of SuperbaTM Krill Oil.
About Aker BioMarine Antarctic
Aker BioMarine Antarctic is an integrated biotechnology company dedicated to the sustainable harvesting of krill and development of krill-derived biotech products. The company supplies biomarine ingredients through an optimized value chain from raw materials to customers. Aker BioMarine Antarctic's SuperbaTM Krill products are provided with 100% traceability from the Antarctic sea to the end user. Only Aker BioMarine Antarctic’s krill fishery has been awarded Marine Stewardship Council (MSC) Certification.